Clinical Trial Update: Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating add-on sodium benzoate for treatment-resistant schizophrenia, focusing on symptom and cognitive outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Sodium benzoate (sodium benzoate)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Symptom, Cognitive, Schizophrenia | Phase 2 | Status: UNKNOWN